<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609477</url>
  </required_header>
  <id_info>
    <org_study_id>6002-017</org_study_id>
    <nct_id>NCT02609477</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Abuse Potential of Istradefylline</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Istradefylline in Recreational Drug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyowa Kirin Pharmaceutical Development, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the abuse potential of single-doses of istradefylline compared to
      placebo and phentermine in recreational stimulant users. Subjects will participate in an
      outpatient medical Screening visit, a 5-day Qualification (Drug Discrimination) Phase, a
      6-period Treatment Phase, and an outpatient safety Follow-Up visit. Study will be
      approximately 25 weeks total.

      Within 28 days of the Screening visit, eligible subjects will be admitted to the CRU (Day -1)
      for the Qualification Phase. During the Qualification Phase, subjects will receive single
      oral doses of phentermine 60 mg and matching placebo in a randomized, double blind, crossover
      manner, with each drug administration separated by approximately 48 hours (Day 1 and Day 3),
      to ensure that they can discriminate and show positive subjective effects of the active
      controls. Following evaluation of eligibility, subjects may be discharged (those who fail
      Qualification criteria) or remain in the CRU (those who pass criteria and are eligible) and
      then proceed directly to the Treatment Phase. The washout interval between last drug
      administration in the Qualification Phase and first drug administration in the Treatment
      Phase will be at least 96 hours (4 days).

      Following confirmation of eligibility from the Qualification Phase, subjects will be
      randomized to one of 6 treatment sequences according to a 6x6 Williams square. Subjects will
      receive single oral doses of each of the 6 treatments in a randomized, double-blind,
      crossover manner, Istradefylline 40 mg, Istradefylline 80 mg, Istradefylline 160 mg,
      Phentermine 45 mg, Phentermine 90 mg, Placebo.

      Each drug administration will be separated by at least 21 days. Serial pharmacodynamic
      evaluations will be conducted up to 24 hours after each study drug administration to confirm
      exposure to istradefylline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Liking VAS</measure>
    <time_frame>24 hours</time_frame>
    <description>To evaluate the abuse potential of istradefylline compared to phentermine and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-SSRS (Columbia Suicide Severity Rating Scale)</measure>
    <time_frame>24 hours</time_frame>
    <description>To evaluate the safety and tolerability of istradefylline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alerness/Drowsiness, Agitation/Relaxation VAS</measure>
    <time_frame>24 hours</time_frame>
    <description>To evaluate the safety and tolerability of istradefylline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffine Withdrawal/Symptom Questionnaire</measure>
    <time_frame>24 hours</time_frame>
    <description>To evaluate the safety and tolerability of istradefylline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking, Take Drug Again VAS</measure>
    <time_frame>24 hours</time_frame>
    <description>To evaluate the safety and tolerability of istradefylline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Similarity VAS</measure>
    <time_frame>24 hours</time_frame>
    <description>To evaluate the safety and tolerability of istradefylline.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Drug Abuse</condition>
  <arm_group>
    <arm_group_label>Istradefylline 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg istradefylline (1 × 40 mg tablet + 3 × placebo tablets + 3 × placebo capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Istradefylline 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg istradefylline (2 × 40 mg tablets + 2 × placebo tablets + 3 × placebo capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Istradefylline 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 mg istradefylline (4 × 40 mg tablets + 3 × placebo capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phentermine 45 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 mg phentermine (4 x placebo tablets + 3 × 15 mg phentermine hydrochloride capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phentermine 90 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>90 mg phentermine (4 × placebo tablets + 3 × 30 mg phentermine hydrochloride capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (4 × placebo tablets + 3 × placebo capsules)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Istradefylline</intervention_name>
    <description>Istradefylline 40, 80, 160 mg</description>
    <arm_group_label>Istradefylline 40 mg</arm_group_label>
    <arm_group_label>Istradefylline 80 mg</arm_group_label>
    <arm_group_label>Istradefylline 160 mg</arm_group_label>
    <other_name>6002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine 45 mg</intervention_name>
    <description>Phentermine 45 or 90 mg</description>
    <arm_group_label>Phentermine 45 mg</arm_group_label>
    <arm_group_label>Phentermine 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Istradefylline 40 mg</arm_group_label>
    <arm_group_label>Istradefylline 80 mg</arm_group_label>
    <arm_group_label>Istradefylline 160 mg</arm_group_label>
    <arm_group_label>Phentermine 45 mg</arm_group_label>
    <arm_group_label>Phentermine 90 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who will provide written informed consent

          -  Healthy volunteer, male and female between 18 and 55 years of age, inclusive

          -  Subjects with a body mass index (BMI) within 18.0 to 33.0 kg/m2, inclusive

          -  Subjects who are recreational drug user

        Exclusion Criteria:

          -  Subjects who have an alcohol or substance dependence within the 12 months

          -  Subjects who have ever been in treatment for substance use disorder

          -  Subjects who consume on average more than 5 servings of caffeinated beverages per day

          -  Subjects with a history of or presence of any clinically significant cardiovascular
             disease

          -  Subject with hyperthyroidism or glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyowa Hakko Kirin Pharma, Inc.</last_name>
    <role>Study Chair</role>
    <affiliation>Kyowa Hakko Kirin Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recreational stimulant users</keyword>
  <keyword>Recreational Drug Users</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentermine</mesh_term>
    <mesh_term>Istradefylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

